Hospital Universitario de Donostia-ko ikertzaileekin lankidetzan egindako argitalpenak (41)

2022

  1. Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson's disease: A randomized controlled trial

    Brain Stimulation

2019

  1. Parkinson’s disease with mild cognitive impairment: severe cortical thinning antedates dementia

    Brain Imaging and Behavior, Vol. 13, Núm. 1, pp. 180-188

2018

  1. Machine learning based analysis of FDG-PET image data for the diagnosis of neurodegenerative diseases

    Frontiers in Artificial Intelligence and Applications

  2. Mitochondrial activity in the frontal cortex area 8 and angular gyrus in Parkinson's disease and Parkinson's disease with dementia

    Brain Pathology, Vol. 28, Núm. 1, pp. 43-57

  3. Phenomenology and disease progression of chorea-acanthocytosis patients in Spain

    Parkinsonism and Related Disorders, Vol. 49, pp. 17-21

  4. Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population

    Neurobiology of Aging, Vol. 70, pp. 325.e1-325.e5

  5. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study

    Movement Disorders, Vol. 33, Núm. 11, pp. 1809-1813

  6. Transcriptomic integration of D4R and MOR signaling in the rat caudate putamen

    Scientific Reports, Vol. 8, Núm. 1

  7. Treatable inherited rare movement disorders

    Movement Disorders, Vol. 33, Núm. 1, pp. 21-35

  8. Using Kinect to classify Parkinson's disease stages related to severity of gait impairment

    BMC Bioinformatics, Vol. 19, Núm. 1

  9. «Apuntes en Neurologia»: una sintesis de la evidencia en trastornos neurologicos comunes paroxisticos y en trastornos neurodegenerativos

    Revista de neurologia, Vol. 67, Núm. s01, pp. S1-S21

2017

  1. Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists

    World Neurosurgery, Vol. 99, pp. 41-46

  2. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study

    Movement Disorders, Vol. 32, Núm. 7, pp. 1066-1073

2016

  1. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease

    Movement Disorders, Vol. 31, Núm. 6, pp. 861-881

  2. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression

    BMC Neurology, Vol. 16, Núm. 1

  3. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2R1441G Parkinson's disease

    Movement Disorders, Vol. 31, Núm. 3, pp. 335-343

  4. Erratum to: COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression [BMC Neurol. 16, (2015), 26] DOI: 10.1186/s12883-016-0548-9

    BMC Neurology

  5. Genetic Mutation Analysis of Parkinson’s Disease Patients Using Multigene Next-Generation Sequencing Panels

    Molecular Diagnosis and Therapy, Vol. 20, Núm. 5, pp. 481-491

  6. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment

    Human Brain Mapping, Vol. 37, Núm. 3, pp. 968-977

2015

  1. Cambios en la sustancia gris en pacientes con enfermedad de parkinson y bloqueos de la marcha

    Revista de Neurologia